# NCT05116189 (NCT05116189)

> Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05116189
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Ovarian Cancer; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms
- Interventions: Pembrolizumab; Paclitaxel; Bevacizumab; Placebo for pembrolizumab; Docetaxel
- Enrollment: 643
- Primary outcome: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Cell Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS] ≥1)
- Primary outcome: PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants

## Commentary we found

- YouTube: 34
- Podcasts: 23
- X threads: 16

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct05116189

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05116189", "email": "<work email>"}; the inbox owner confirms by the emailed link.